dalteparin has been researched along with Adverse Drug Event in 13 studies
Dalteparin: A low-molecular-weight fragment of heparin, prepared by nitrous acid depolymerization of porcine mucosal heparin. The mean molecular weight is 4000-6000 daltons. It is used therapeutically as an antithrombotic agent. (From Merck Index, 11th ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| " Major bleeding occurred in 22 of 576 patients on apixaban (3." | 9.41 | Bleeding with Apixaban and Dalteparin in Patients with Cancer-Associated Venous Thromboembolism: Results from the Caravaggio Study. ( Ageno, W; Agnelli, G; Bauersachs, R; Becattini, C; Cohen, A; Gussoni, G; Huisman, M; Vedovati, MC, 2021) |
| " Major bleeding occurred in 22 of 576 patients on apixaban (3." | 5.41 | Bleeding with Apixaban and Dalteparin in Patients with Cancer-Associated Venous Thromboembolism: Results from the Caravaggio Study. ( Ageno, W; Agnelli, G; Bauersachs, R; Becattini, C; Cohen, A; Gussoni, G; Huisman, M; Vedovati, MC, 2021) |
| "Dalteparin was injected s." | 2.74 | Study of bioaccumulation of dalteparin at a prophylactic dose in patients with various degrees of impaired renal function. ( Brodmann, D; Fischer, AG; Schmid, P; Wuillemin, WA, 2009) |
| "Eight (1." | 2.73 | Safety of deep venous thrombosis prophylaxis with low-molecular-weight heparin in brain surgery. Prospective study on 746 patients. ( Chibbaro, S; Tacconi, L, 2008) |
| " The only registered antidote for ENX, protamine sulfate (PS), has 60% efficacy and can cause severe adverse side effects." | 1.62 | Reversal Activity and Toxicity of Heparin-Binding Copolymer after Subcutaneous Administration of Enoxaparin in Mice. ( Kalaska, B; Miklosz, J; Mogielnicki, A; Pawlak, D; Swieton, J; Szczubialka, K; Yusa, SI, 2021) |
| "04) were the only significant independent predictors for any major adverse event." | 1.37 | Safety of coronary artery bypass surgery during therapeutic oral anticoagulation. ( Airaksinen, KE; Biancari, F; Karjalainen, P; Kuttila, K; Laitio, T; Lip, GY; Mikkola, R; Porela, P, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (30.77) | 29.6817 |
| 2010's | 5 (38.46) | 24.3611 |
| 2020's | 4 (30.77) | 2.80 |
| Authors | Studies |
|---|---|
| Bai, W | 1 |
| Zhang, X | 2 |
| Sun, S | 1 |
| Wang, Q | 1 |
| Li, C | 1 |
| Zhao, A | 1 |
| Chen, T | 1 |
| Lan, L | 1 |
| Sun, W | 1 |
| Yu, J | 1 |
| Lu, B | 1 |
| Chen, L | 1 |
| Sun, L | 1 |
| Yu, Z | 1 |
| Wu, B | 1 |
| Xiong, Y | 1 |
| Swieton, J | 1 |
| Miklosz, J | 1 |
| Yusa, SI | 1 |
| Szczubialka, K | 1 |
| Pawlak, D | 1 |
| Mogielnicki, A | 1 |
| Kalaska, B | 1 |
| Cimminiello, C | 1 |
| Prandoni, P | 1 |
| Agnelli, G | 2 |
| Di Minno, G | 1 |
| Polo Friz, H | 1 |
| Scaglione, F | 1 |
| Boracchi, P | 1 |
| Marano, G | 1 |
| Harenberg, J | 1 |
| Heer, T | 1 |
| Juenger, C | 1 |
| Gitt, AK | 1 |
| Bauer, T | 1 |
| Towae, F | 1 |
| Zahn, R | 1 |
| Senges, J | 1 |
| Zeymer, U | 1 |
| Imberti, D | 1 |
| Pierfranceschi, MG | 1 |
| White, HD | 1 |
| Aylward, PE | 1 |
| Gallo, R | 1 |
| Bode, C | 1 |
| Steg, G | 1 |
| Steinhubl, SR | 1 |
| Montalescot, G | 1 |
| Airaksinen, KE | 1 |
| Biancari, F | 1 |
| Karjalainen, P | 1 |
| Mikkola, R | 1 |
| Kuttila, K | 1 |
| Porela, P | 1 |
| Laitio, T | 1 |
| Lip, GY | 1 |
| Montero Ruiz, E | 1 |
| Baldominos Utrilla, G | 1 |
| López Álvarez, J | 1 |
| Santolaya Perrin, R | 1 |
| Ageno, W | 1 |
| Vedovati, MC | 1 |
| Cohen, A | 1 |
| Huisman, M | 1 |
| Bauersachs, R | 1 |
| Gussoni, G | 1 |
| Becattini, C | 1 |
| Schmid, P | 1 |
| Brodmann, D | 1 |
| Fischer, AG | 1 |
| Wuillemin, WA | 1 |
| Rodger, MA | 1 |
| Ramsay, T | 1 |
| MacKinnon, M | 1 |
| Westphal, M | 1 |
| Wells, PS | 1 |
| McCormick, B | 1 |
| Knoll, G | 1 |
| Chibbaro, S | 1 |
| Tacconi, L | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| An International Phase 2-3, Stratified, Randomized, Open-label, Parallel-group Clinical Trial to Evaluate the Safety and Efficacy of a Single Intravenous Bolus of Enoxaparin Versus Intravenous Unfractionated Heparin in Patients Undergoing Non-emergent Per[NCT00077844] | Phase 2/Phase 3 | 3,532 participants (Anticipated) | Interventional | 2004-01-31 | Completed | ||
| Pharmacokinetics of Dalteparin in Patients With Impaired Renal Function[NCT00264693] | 96 participants (Actual) | Observational | 2006-01-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for dalteparin and Adverse Drug Event
| Article | Year |
|---|---|
Thromboprophylaxis with enoxaparin and direct oral anticoagulants in major orthopedic surgery and acutely ill medical patients: a meta-analysis.
Topics: Administration, Oral; Anticoagulants; Clinical Trials, Phase III as Topic; Drug-Related Side Effects | 2017 |
5 trials available for dalteparin and Adverse Drug Event
| Article | Year |
|---|---|
Hematomas of at least 5 cm and outcomes in patients undergoing elective percutaneous coronary intervention: insights from the SafeTy and Efficacy of Enoxaparin in PCI patients, an internationaL randomized Evaluation (STEEPLE) trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Drug-Related Side Effects and Adverse Reaction | 2010 |
Bleeding with Apixaban and Dalteparin in Patients with Cancer-Associated Venous Thromboembolism: Results from the Caravaggio Study.
Topics: Aged; Dalteparin; Drug-Related Side Effects and Adverse Reactions; Female; Fibrinolytic Agents; Gast | 2021 |
Study of bioaccumulation of dalteparin at a prophylactic dose in patients with various degrees of impaired renal function.
Topics: Aged; Aged, 80 and over; Anticoagulants; Cohort Studies; Dalteparin; Drug-Related Side Effects and A | 2009 |
Tinzaparin versus dalteparin for periprocedure prophylaxis of thromboembolic events in hemodialysis patients: a randomized trial.
Topics: Aged; Aged, 80 and over; Dalteparin; Dose-Response Relationship, Drug; Drug Administration Schedule; | 2012 |
Safety of deep venous thrombosis prophylaxis with low-molecular-weight heparin in brain surgery. Prospective study on 746 patients.
Topics: Anticoagulants; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; F | 2008 |
7 other studies available for dalteparin and Adverse Drug Event
| Article | Year |
|---|---|
Effect of low-molecular-weight heparins on anti-Xa peak levels and adverse reactions in Chinese patients with recurrent spontaneous abortion: a single-center, observational study.
Topics: Abortion, Habitual; Adult; Anticoagulants; Asian People; Blood Coagulation; China; Dalteparin; Drug | 2021 |
Localized and Generalized Skin Adverse Drug Reactions to Nadroparin Calcium Injection in 6 Cases of Pregnant Women.
Topics: Drug-Related Side Effects and Adverse Reactions; Female; Humans; Nadroparin; Pregnancy; Pregnant Wom | 2022 |
Reversal Activity and Toxicity of Heparin-Binding Copolymer after Subcutaneous Administration of Enoxaparin in Mice.
Topics: Animals; Anticoagulants; Blood Coagulation Tests; Drug-Related Side Effects and Adverse Reactions; E | 2021 |
Efficacy and safety of optimized antithrombotic therapy with aspirin, clopidogrel and enoxaparin in patients with non-ST segment elevation acute coronary syndromes in clinical practice.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Drug Evaluation; Drug Therapy, Combination; Dru | 2009 |
Successful protein C concentrate administration during initiation of oral anticoagulation in adult patients with severe congenital protein C deficiency: report of two cases.
Topics: Adult; Anticoagulants; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; E | 2008 |
Safety of coronary artery bypass surgery during therapeutic oral anticoagulation.
Topics: Aged; Anticoagulants; Blood Loss, Surgical; Case-Control Studies; Coronary Artery Bypass; Drug-Relat | 2011 |
Effectiveness and safety of thromboprophylaxis with enoxaparin in medical inpatients.
Topics: Aged; Comorbidity; Drug-Related Side Effects and Adverse Reactions; Emergency Medical Services; Enox | 2011 |